Laura Doni

Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i> –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

James Chih‐Hsin Yang, Dae Ho Lee, Jong‐Seok Lee et al. · Journal of Clinical Oncology · 2024 · 142 citations · Full text

Medicine, Oncology, Pharmacology +14

Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC)

Francesco Di Costanzo, Paolo Carlini, Laura Doni et al. · British Journal of Cancer · 2005 · 99 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

David Miles, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2021 · 89 citations · Full text

Medicine, Oncology, Pharmacology +17

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

Arlene O. Siefker‐Radtke, Nobuaki Matsubara, S.H. Park et al. · Annals of Oncology · 2023 · 80 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Primary Cardiac Angiosarcoma: A Fatal Disease

Lorenzo Antonuzzo, Virginia Rotella, Francesca Mazzoni et al. · Case Reports in Medicine · 2009 · 75 citations · Full text

Medicine, Cardiology, Oncology +14